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Abstract 
Background: Recent studies alluded to the alarming scale of poor anti‑malarial drug quality in malaria‑endemic 
countries, but also illustrated the major geographical gaps in data on anti‑malarial drug quality from endemic coun‑
tries. Data are particularly scarce from Central Africa, although it carries the highest burden of malaria. The aim of this 
medicine quality field survey was to determine the prevalence of poor‑quality anti‑malarial drugs in Gabon.
Methods: A field survey of the quality of anti‑malarial drugs in Gabonese pharmacies was conducted using the 
Global Pharma Health Fund Minilab® tests, following the Medicine Quality Assessment Reporting Guidelines. Anti‑
malarial drugs were purchased randomly from selected pharmacies in Gabon. Semi‑quantitative thin‑layer chroma‑
tography (TLC) and disintegration testing were carried out to measure the concentration of active pharmaceutical 
ingredients (APIs). The samples failing the TLC test were analysed by high‑performance liquid chromatography. 
Following the collection of anti‑malarial drugs, a street survey was conducted to understand where people purchase 
their anti‑malarial drugs.
Results: A total of 432 samples were purchased from 41 pharmacies in 11 cities/towns in Gabon. The prevalence 
of poor‑quality anti‑malarial drugs was 0.5% (95% CI 0.08–1.84%). Two out of 432 samples failed the MiniLab® semi‑
quantitative TLC test, of which a suspected artemether‑lumefantrine (AL) sample was classified as falsified and one 
sulfadoxine‑pyrimethamine (SP) sample as substandard. High performance liquid chromatography with ultraviolet 
photo diode array detection analysis confirmed the absence of APIs in the AL sample, and showed that the SP sample 
did contain the stated APIs but the amount was half the stated dose. Of the people interviewed, 92% (187/203) pur‑
chased their anti‑malarial drugs at a pharmacy.
Conclusion: Using the GPHF Minilab®, the prevalence of poor‑quality anti‑malarial drugs is far lower than anticipated. 
The findings emphasize the need for randomized and robust sampling methods in order to collect representative 
data on anti‑malarial drug quality.
Trial registration: NTR4341 (Dutch Trial Registry)
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Background
Plasmodium falciparum malaria is estimated to cause 
528,000 deaths and 163 million clinical episodes in Africa 
[1]. Early diagnosis and treatment with appropriate 
anti-malarial drugs can prevent severe illness and lethal 
outcome [2–4]. Therefore, it is crucial that the adminis-
tered anti-malarial drugs are of acceptable quality [5]. In 
Gabon, the majority of anti-malarial drugs are purchased 
directly by the patient or caretaker from the pharmacy 
(licensed and unlicensed) for self- or home treatment. 
There is no anti-fake medicine programme, nor an effec-
tive drug regulatory system in Gabon (Additional file 1). 
Gabon does not receive international donor support for 
anti-malarial medicines. The national malaria control 
programme of Gabon does not provide anti-malarials for 
free. Whether quality assured or falsified, anti-malarial 
drugs have not been reported from the Gabonese mar-
kets as from the neighbouring countries. The spread 
of poor-quality [6, 7] (e.g., counterfeit or falsified) anti-
malarial drugs may pose an obstacle to effective malaria 
control. Poor-quality anti-malarial drugs have serious 
consequences for public health [5]. Drugs with too lit-
tle, or devoid of active pharmaceutical ingredients (APIs) 
may cause increased morbidity and mortality [8]. Also, 
low concentrations of APIs in poor-quality drugs will 
result in sub-therapeutic concentrations of the drug 
in  vivo, which may contribute to the selection of resist-
ant parasites [9]. Furthermore, the use of poor-quality 
anti-malarial drugs leads to financial loss for patients 
and their families, healthcare systems and pharmaceuti-
cal companies producing the genuine product [10]. The 
general public can lose confidence in a pharmaceutical 
brand, drugs, pharmacies, and healthcare providers [11].
A systematic review in 2014 illustrated the alarm-
ing scale of poor anti-malarial drug quality in malaria-
endemic countries, but also showed major geographical 
gaps, with no published information on the quality of 
anti-malarial drugs from 60.6% (63/104) of the malaria-
endemic countries) [12]. Using the Worldwide Antima-
larial Resistance Network (WWARN) [13] database, it 
was demonstrated that out of 9,348 anti-malarial drugs 
collected (compiled from 130 publications in total), 
Resume 
Contexte: Des études récentes ont fait allusion à l’ampleur alarmante sur la qualité des médicaments antipaludiques 
dans les pays d’endémie. Elles ont aussi illustré les principales lacunes des données géographiques concernant les 
médicaments antipaludiques dans les pays endémiques. Les données sont particulièrement rares en Afrique centrale, 
bien que cette région porte le plus lourd fardeau du paludisme. Le but de cette enquête sur le terrain était de déter‑
miner la prévalence des médicaments antipaludiques de mauvaise qualité au Gabon.
Méthodes: Une enquête sur le terrain a été réalisée sur la qualité des médicaments antipaludiques dans les pharma‑
cies gabonaises en utilisant les tests ‘Global Pharma Health Fund Minilab®’, suivant la ‘Medicine Quality Assessment 
Reporting Guidelines (MEDQUARG)’. Les médicaments antipaludiques ont été achetés dans des pharmacies choisies 
au hasard au Gabon. La chromatographie semi‑quantitative en couche mince (CCM) et le test de désintégration ont 
été effectués pour mesurer la concentration d’ingrédients pharmaceutiques actifs (API). Les échantillons qui n’ont pas 
réussi le test CCM ont été analysés par chromatographie en phase liquide à haute performance. Après la collecte des 
médicaments antipaludiques, une enquête communitaire a été menée pour comprendre où les gens achètent leurs 
médicaments.
Résultats: Un total de 432 échantillons ont été achetés dans 41 pharmacies de 11 villes au Gabon. La prévalence 
de médicaments antipaludiques de mauvaise qualité était de 0,5% (IC 95% de 0,08 à 1,84%). Sur les 432 échantillons, 
le test semi‑quantitatif de chromatographie sur couche mince Minilab® n’a permis de détecter aucune substance 
active sur deux échantillons, dont un échantillon d’artéméther‑luméfantrine (AL) suspecté contrefait et un échantil‑
lon de sulfadoxine‑pyriméthamine (SP) ont été classées échantillon de qualité inférieure. L’analyse pour la détection 
d’APIs  dans l’échantillon AL par chromatographie liquide à haute performance avec photo ultraviolet de réseau de 
diodes a confirmé l’absence d’API et a montré que l’échantillon de SP contient les énoncés API mais la quantité était la 
moitié de la dose indiquée. Parmi les personnes interrogées, 92% (187/203) ont acheté leurs médicaments dans une 
pharmacie.
Conclusion: L’utilisation du GPHF Minilab®, la prévalence des médicaments antipaludiques de mauvaise qualité est 
grandement inférieur à celle prévue. Les résultats soulignent la nécessité pour les méthodes d’échantillonnage aléa‑
toire et robustes afin de recueillir des données représentatives sur la qualité des médicaments antipaludiques.
Keywords: Artemisinin combination therapy (ACT), Central Africa, Counterfeit, Falsified, Field survey, Gabon, Malaria, 
Medicine quality, MEDQUARG, Sub‑standard
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30.1% (2,813) failed chemical/packaging quality tests 
with 39.3% classified as falsified; 2.3% as sub-standard 
and 58.3% as poor-quality, without evidence available to 
categorize them as either sub-standard or falsified [12]. 
There are few reports originating from Central Africa. 
Also for Gabon, systematic data on the geography and 
epidemiology of poor-quality anti-malarial drugs is 
scarce. Gabon is a high-endemicity country for malaria 
[14–16]. A study in 2011, assessing the quality of chloro-
quine tablets in 12 African countries collected two chlo-
roquine samples from the capital of Gabon (Libreville), 
which were both of good quality [17]. The World Health 
Organization (WHO) investigation in 2003 collected 
25 chloroquine samples (29% poor-quality) and ten 
sulfadoxine-pyrimethamine samples (100% good qual-
ity) from pharmacies in Libreville. A limited number of 
reports are available from neighbouring countries Came-
roon [5, 17–22], Equatorial Guinea [23] and the Republic 
of Congo [5].
The aim of this study was to determine the prevalence 
of poor-quality anti-malarial drugs in Gabon, which lacks 
an effective national product quality monitoring pro-
gramme (see Additional file  1). Information about the 
quality of anti-malarial drugs is important for improving 
malaria treatment and to successfully run malaria control 
programmes [24, 25].
Methods
Registration and reporting
This medicine quality field survey was registered in 
advance (30 Dec 2013) in The Netherlands Trial Reg-
istry (NTR): NTR4341 [26]. This report follows, where 
appropriate, the Medicine Quality Assessment Reporting 
Guidelines (MEDQUARG) [27, 28]. Also, the costs of this 
study are reported [29] (Additional file 2).
Scientific research and ethical committee statement
Scientific clearance was obtained from the Scientific 
Review Committee (SRC) of the Centre de Recherches de 
Médicales de Lambaréné (CERMEL), Albert Schweitzer 
Hospital (SRC number: 2013.11; Additional file  3). The 
Ethical Committee of CERMEL decided that ethical 
approval of this study was not required as this study is a 
quality assurance in healthcare study, no humans having 
been subjected to it [30].
Study area
Gabon (an upper-middle income country, GDP $19.34 
billion, 2013) straddles the Equator. About 80% of its 
267,667 km2 area is covered by dense tropical rainforest. 
The population of Gabon is estimated to be around 1.6 
million inhabitants (6.3 inhabitants/km2), 86.2% of whom 
live in urban areas. CERMEL is based in Lambaréné, the 
capital of the Moyen-Ogooué Province, a semi-urban 
town of about 30,000 inhabitants surrounded by vil-
lages. Gabon is administratively divided into nine prov-
inces, with villages mainly located along roads and rivers. 
Gabon is a highly malaria-endemic country. The offi-
cial first-line treatment for uncomplicated falciparum 
malaria is artesunate  +  amodiaquine (AS  +  AQ) [31] 
or artemether-lumefantrine (AL) and severe falciparum 
malaria is treated with intravenous quinine. Intramus-
cular use of artemether or intravascular artesunate is not 
common in Gabon.
Primary and secondary outcomes
The primary outcome was the proportion (percentage) of 
poor-quality anti-malarial drugs in pharmacies in Gabon. 
Secondary outcomes were the proportion of outlets sell-
ing poor-quality anti-malarial drugs and availability of 
anti-malarial drugs that are no longer recommended as 
first- or second-line treatment in Gabon or by WHO. The 
following secondary outcome was added during the study 
to assess the external validity of the field survey: to deter-
mine where people purchased their anti-malarial drugs.
Definitions
The overarching term ‘poor-quality drugs’ is used to 
describe the different categories: falsified medicines are 
fake medicines that are designed to mimic real medi-
cines; counterfeit medicines are medicines that do not 
comply with intellectual-property rights or that infringe 
trademark law.
Timing and location of the survey
The field survey was conducted in January 2014 in 
Gabon. The six (out of nine) most populated provinces 
(ISO 3166-2:GA) were selected: Estuaire; Haut-Ogooué, 
Moyen-Ogooué, Ngounié, Ogooué-Maritime, and 
Woleu-Ntem. Selected locations were: Libreville (capi-
tal), Franceville, Lambaréné, Mouila, Port-Gentil, Oyem, 
Bitam, Owendo, Fougamou, Makouke, Bifoun, Gamba, 
and Lopé (Figure 1).
Sampling design and sample size
There are approximately 75 open and fully function-
ing pharmacies in Gabon (2013) [32]. Pharmacies were 
randomly selected. The randomization procedure was 
performed by BJV using statistical software (nQuery 
Advisor® Version 7.0. Statistical Solutions, Cork, Ire-
land) on the day before the actual sampling. A full list 
provided by the Health Authorities of Gabon and a list 
from the National Health Assurance Company (La 
Caisse Nationale d’Assurance Maladie et de Garan-
tie Sociale du Gabon [33], CNAGMS) with registered/
licensed pharmacies and dispensaries was prepared 
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(before sampling) to allow for proper randomization 
procedures. This list was accomplished with (unlisted) 
pharmacies by local nurses and fieldworkers. In total, 
six pharmacies were found which were missing on the 
CNAGMS list of pharmacies in Gabon. In Lambaréné 
(Moyen-Ogooué Province), where the CERMEL is based, 
all known pharmacies (n =  7) were sampled during the 
first week of the sampling period and thus not randomly 
selected. In all other areas, approximately 50% of the 
pharmacies were randomly selected in all neighbour-
hoods. Hospitals (except for the Albert Schweitzer Hos-
pital), markets, grocery shops, and street peddlers were 
not visited because regulations for drug selling are in 
place; previsits by local nurses yielded little evidence (if 
any) of anti-malarial drugs sold there. The appropriate 
sample size and strategy is challenging, since data of the 
prevalence of poor-quality anti-malarial drugs are very 
scarce for Gabon. Thus, the most conservative sample 
size is given by using an unknown prevalence [hypothe-
sized 50% frequency of outcome factor in the population 
(p)]. To determine the actual prevalence of poor-quality 
drugs available in Gabon with a precision of 5% with 95% 
confidence intervals (z = 1.96), a random sample of 384 
was needed. The following equation was used: sample size 
n = [DEFF ∗Np(1 − p)]/ [(d2/Z21−α/2) ∗ (N− 1)+ p∗  
(1− p)]. The sample size was calculated with OpenEpi 
(Open Source Epidemiologic Statistics for Public Health) 
version 3.03 [34].
Sampling procedure
A Gabonese ‘mystery shopper’ (JM, nurse, of Gabonese 
nationality) conducted the actual sampling process 
in Moyen-Ogooué (177/432 samples) and was trained 
utilizing standard sampling guidelines. She dressed 
according to regular Gabonese standards and gave no 
indication that she was not a regular shopper. A stand-
ard scenario was used: she asked which anti-malarial 
drugs were for sale. Subsequently, she purchased one 
full child/adult treatment in their original packag-
ing of each of the available anti-malarials and of each 
available brand, but not of each available batch. Sam-
ples included drugs sold in the manufacturer’s original 
packaging as well as those distributed loose, often in 
plastic bags. Surprisingly, sellers never asked questions. 
Figure 1 Map of sampling sites in Gabon (Google Maps).
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Although the US Pharmacopeia (USP) recommends 30 
dosage units [35] for a single tablet of the same lot num-
ber from each location, this was not deemed practically 
feasible in the Gabonese setting, and also too expensive. 
For logistical reasons the other 255/432 (60%) samples 
were collected by the investigators. Anti-malarial drugs 
purchased included: AL, AS  +  AQ, AS  +  sulfadox-
ine, AS-mefloquine, dihydroartemisinin-piperaquine, 
dihydroartemisinin-piperaquine-trimethoprim, arte-
misinin-piperaquine, artemisinin-naphtoquine, qui-
nine, sulfadoxine-pyrimethamine (SP), mefloquine, 
proguanil, atovaquone-proguanil, proguanil-chloro-
quine, pyrimethamine and chloroquine. Other anti-
malarial drugs were not purchased. Only solid dosage 
forms were collected (no liquid formulations). To avoid 
potential bias in subsequent sampling rounds, the exact 
reason for sampling medicines was not shared with the 
seller. Results were not reported back to the seller. For 
every sample collected, the collector completed and 
signed the sample collection form (including GPS loca-
tions) (Additional file 4) as soon as possible after leav-
ing the point of sale and before performing the next 
purchase. Once purchased, all drugs were stored until 
testing at room temperature (in an air-conditioned 
room) with no sunlight. Humidity could not be con-
trolled. Tests were completed at the laboratory of the 
Academic Medical Centre (AMC, The Netherlands) 
within 3 months of sample collection.
Questionnaire
To determine where people purchased their anti-malar-
ial drugs, a questionnaire was presented to food market 
dwellers in Lambaréné as well as at PK (‘point kilomètre’) 
8 Le Marché Bananes (a transportation hub) and Marché 
du Mont-Bouët in Libreville. The survey was conducted 
after the purchase of the anti-malarial drugs. The most 
important question in this survey was: “where do you buy 
anti-malarial drugs?”.
Storage and shipment of samples
Before shipment by air, samples were stored at CER-
MEL under appropriate storage conditions. The samples 
arrived within 36  h at AMC in Amsterdam, The Neth-
erlands. Samples were protected by appropriate packag-
ing (primary container and additional packaging) during 
shipment by air.
Chemical and packaging analysis
Samples were analysed at the Internal Medicine Research 
Laboratory of the AMC between February 2014 and 
April 2014 by BJV and JMG. The chemical analysis was 
performed unblinded to packaging. The Global Pharma 
Health Fund (GPHF) Minilab® (Merck Darmstadt, 
Germany) was used to run semi-quantitative thin-layer 
chromatography (TLC) and disintegration tests on each 
sample to determine the presence and relative concen-
tration of APIs [36]. Expired drugs were also tested. The 
MiniLab® protocols award products a ‘pass’ for TLC if 
80% or more of the labelled active ingredient(s) is pre-
sent. For fixed-dose combinations (e.g., AL) and SP, ‘pass’ 
was awarded only if both active ingredients met this 
standard. TLC is an accepted method to assess the qual-
ity of drugs [37, 38]. The MiniLab protocols have been 
reviewed by the Promoting the Quality of Medicines 
(PQM) programme operated by the USP Convention. 
Each sample/test was run twice on separate days (once by 
BJV, once by JMG), with the assumption that the result 
most consistent with the reference was recorded. Thus, 
every API in every sample was tested twice. Standard 
operating procedures (SOP) provided with the Minilab 
were used [36]. Quality control of the GPHF MiniLab® 
was performed daily before the drug testing and con-
sisted of performing TLC on Minilab-reference samples 
for the anti-malarial drug analysed. In addition, Minilab 
reagents were quality control tested, using reference sam-
ples when a new lot was introduced. Samples were also 
tested to see if they disintegrated in purified water, fol-
lowing the guidelines of the European Pharmacopeia (EP) 
[39]. For this, apparatus A as described in the EP 2.9.1. 
was used at the laboratory of the Pharmaceutical Tech-
nology and Biopharmacy Department of Utrecht Univer-
sity (Utrecht, The Netherlands). Since the disintegration 
test requires six tablets per test, not all samples could be 
analysed. To include as many samples as possible, it was 
decided to test the samples per batch number instead of 
per sample. All samples with the same batch (or LOT) 
number, were expected to be homogeneous [40]. Samples 
failing TLC were analysed using the high-performance 
liquid chromatography with ultraviolet photo-diode array 
detection (HPLC–UV-PDA [41] February 2015 in a ref-
erence laboratory at the London School of Hygiene and 
Tropical Medicine) to quantify the amount of APIs pre-
sent in each sample. This was compared with the stated 
dose on the packaging and the spectra achieved using a 
quality assured sample. For artemisinin derivatives, the 
artemisinin derivative screening test (ADST) was con-
ducted according to an earlier published method [38]. 
Not all samples were analysed by HPLC–UV-PDA (the 
gold standard) due to lack of funding.
The packaging analysis was developed in line with 
previously published research [5, 27]. For the packag-
ing analysis, genuine samples were requested by email 
from the manufacturers using a standard letter; with 
two reminders sent 2 and 4 weeks after the first email. 
Unfortunately no genuine anti-malarial samples were 
received.
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Statistical analysis
Descriptive statistics were performed using SPSS 20.0 
statistical package (SPSS Inc., Chicago, MI, USA). The 
confidence interval of the prevalence estimate was cal-
culated using the Wilson procedure with a correction 
for continuity. Fisher’s exact test was used to calculate 
the difference between the number of poor-quality drugs 
of the Gabonese mystery shopper versus two European 
researchers. Inter-observer reliability (for chemical anal-
ysis) was calculated using the Kappa (κ) statistic [42].
Sharing data with Medicine Regulatory Agency
The results of this field survey were shared with the Med-
icine Regulatory Agency (MRA) in Gabon, the Direc-
tor of Health of the Province Moyen-Ogooué and Rapid 
Alert of the WHO.
Results
The samples purchased in this field survey were read-
ily available over the counter without prescription in all 
pharmacies. In total, 432 full anti-malarial treatments 
were collected from 41 pharmacies and one hospital 
(Albert Schweitzer Hospital, Lambaréné) in 11 cities/
towns in Gabon (Table  1; Figure  1). From the collected 
data, 55% (41/75) of pharmacies in Gabon were surveyed. 
The ‘class’ of pharmacy and licensing status (e.g., public, 
private for profit, private not for profit, informal) was not 
determined and the drug sellers were not interviewed.
Of the 432 collected samples, 338 (78%) were arte-
misinin-based combination therapy (ACT). AS + AQ, the 
national recommended first-line treatment for falciparum 
malaria, comprised 10% of the total samples (n = 42). The 
second-line anti-malarial drug combination is AL and the 
third-line drug combination is dihydroartemisinin-pipe-
raquine. An ACT was available in every surveyed phar-
macy, but AS-AQ was only available in 27 pharmacies 
(65%). On average, ten full anti-malarial treatments were 
collected per pharmacy (min–max: 3–20). Two samples 
were expired at the day of purchase, both collected in a 
pharmacy in Lambaréné. They were not classified as sub-
standard. No chloroquine or artesunate monotherapy was 
for sale in all the surveyed pharmacies.
Chemical analysis: semi‑quantitative thin‑layer 
chromatography (TLC)
All samples were analysed in duplicate on separate days 
(Table  2). Inter-observer agreement was good for TLC 
testing (κ =  1, 100% agreement). Thirteen samples were 
expired before analysis, but analysed anyway since they 
were sold. All samples met the requirements for uniform-
ity of UV spots (254 nm light), which meant that all sam-
ples were analysed correctly. Only two of the 432 (0.5%) 
Table 1 Anti-malarial drugs collected
TLC semi-quantitative thin-layer chromatography.
Collected and 
analyzed with 
TLC (%)
Samples included 
in disintegration 
test (% of TLC tested)
Expired 
before 
analysis
TLC 
failures
Disinteg‑ration 
test failures
Average 
costs 
(USD)
ACT
 Artemether‑lumefantrine 177 (41%) 102 (58%) 3 1 0 7.6
 Artesunate‑amodiaquine 42 (10%) 22 (52%) 6 0 0 7.2
 Artesunate‑SP 36 (8%) 26 (72%) 1 0 0 8.5
 Dihydroartemisinin‑pipe‑
raquine
38 (9%) 33 (86%) 1 0 0 9.9
 Artesunate‑mefloquine 22 (5%) 5 (23%) 1 0 0 9.7
 Dihydroartemisinin‑pipe‑
raquine‑ trimethoprim
13 (3%) 12 (92%) 0 0 0 9.3
 Dihydroartemisinin‑SP 7 (2%) 0 (0%) 0 0 0 4.5
 Artemisinin‑piperaquine 2 (<1%) 0 (0%) 0 0 0 10.1
 Artemisinin‑naphtoquine 1 (<1%) 0 (0%) 0 0 0 NR
Other
 Quinine 43 (10%) 34 (79%) 0 1 0 9.6
 Sulphadoxine‑pyrimethamine 40 (9%) 26 (65%) 0 0 1 2.2
 Mefloquine 4 (<1%) 2 (50%) 0 0 0 33.3
 Atovaquone‑proguanil 2 (<1%) 0 (0%) 0 0 0 24.2
 Proguanil 2 (<1%) 0 (0%) 0 0 0 16.5
 Proguanil‑chloroquine 2 (<1%) 0 (0%) 1 0 0 25.2
 Pyrimethamine 1 (<1%) 0 (0%) 0 0 0 NR
Total 432 (100%) 266 (62%) 13 (3%) 2 1 8.1
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Table 2 Summary of formulations tested with the brand name, manufacturer, dose, dosage form, ACT Watch Antimalar-
ial database status and WHO prequalification list
Brand name/manufacturer Generic name and dose ACT Watch Antimalarial 
Database
Antimalarial category
Regulatory 
status in 
Gabon
Alaxin‑SP®, Bliss GVS Pharma LTD, India Dihydroartemisinin + SP tablet 60/500/25 mg Non‑quality assured ACT Unknown
Arco®, Kunming Pharmaceutical Corp, 
China
Artemisinin‑naphthoquine tablet 125/50 mg Non‑quality assured ACT Unknown
Arsiquinoforme®, Sanofi Aventis, Cote 
d’Ivoire
Quinine tablet 250 mg Non‑artemisinin therapy Unknown
Artecom®, Tonghe Pharmaceutical Co. 
Ltd, China
Dihydroartemisinin‑piperaquine‑trimethoprim 
tablet 32/320/90 mg and 16/160/45 mg
Non‑quality assured ACT Unknown
Artedar®, Plethico Pharma Ltd, India Artesunate‑SP, tablet 100/500/25 mg Non‑quality assured ACT Unknown
Artediam®, Adams Pharmaceutical 
(Anhui) Co., Ltd.
Artesunate‑amodiaquine tablet 100/300 mg Not listed, category unknown. Approval at national 
level
Artefan®, Ajanta Pharma Ltd, India Artemether‑lumefantrine tablet 20/120 mg
Artemether‑lumefantrine tablet 80/480 mg
QAACT (Quality‑assured ACT)
Non‑quality assured ACT
A (MA092, 2012‑
Dec‑19)—WHO 
prequalification
Approval at national 
level
Artequick®, Artepharm Co.Ltd, China Artemisinin‑piperaquine tablet 62.5/375 mg Non‑quality assured ACT Unknown
Artequin®, Mepha Ltd, Switzerland Artesunate‑mefloquine tablet 200/250 mg
Artesunate‑mefloquine tablet 100/125 mg
QAACT (Quality‑assured ACT)
Non‑quality assured ACT
B
Artim®, Twight Litaka Pharma Limited 
Ltd, India
Artemether‑lumefantrine tablet 40/240 mg Not listed, category unknown Unknown
Artiz (Forte)®, Alice Pharma  
Pvt Ltd, India
Artemether‑lumefantrine tablet 40/240 mg
Artemether‑lumefantrine tablet 20/200 mg
Dosage not listed, category unknown
Dosage not listed, category unknown
Unknown
ASAQ Denk®, Denk Pharma, Germany Artesunate‑amodiaquine tablet 100/270 mg Non‑quality assured ACT Unknown
Asunate Denk®, Denk Pharma, Germany Artesunate‑SP tablet 200/500/25 mg Non‑quality assured ACT Unknown
Bimalaril®, Bengba Pharmaceutical fac‑
tory, China
Artemether‑lumefantrine tablet 80/480 mg Not listed, manufacturer unknown Approval at national 
level
Chinther®, Alkema Laboratories  
LTD, India
Artemether‑lumefantrine tablet 40/240 mg Not listed, brand and manufacturer 
unknown
Unknown
Co‑Arinate®, Famar Italia Spa, Italy Artesunate‑SP tablet 200/500/25 mg
Artesunate‑SP tablet 100/250/12,5 mg
Not listed, manufacturer unknown
Not listed, manufacturer unknown
Unknown
Coarsucam®, Sanofi Aventis, Morocco Artesunate‑amodiaquine tablet 50/135 mg
Artesunate‑amodiaquine tablet 100/270 mg
Artesunate‑amodiaquine tablet 25/67.5 mg
QAACT (Quality‑assured ACT)
QAACT (Quality‑assured ACT)
QAACT (Quality‑assured ACT)
MA057 (2008‑Oct‑
14)/MA058 2008‑
Oct‑14/MA056 
(2008‑Oct‑14)
WHO prequalifica‑
tion
Coartem®, Novartis Pharma Ag, China, 
Switzerland, USA
Artemether‑lumefantrine tablet 20/120 mg QAACT (Quality‑assured ACT) A‑B (MA026 (a), 
2004‑Apr‑26)
WHO prequalifica‑
tion/FDA approval
Co‑artemax®, GA Pharma, Greece Dihydroartemisinin‑piperaquine tablet 
40/320 mg
Not listed, brand & manufacturer 
unknown
Unknown
Cofantrine®, Bliss Gvs Pharma Ltd, India
Cofantrine®, EGR Pharma, Luxembourg
Artemether‑lumefantrine tablet 20/120 mg and 
80/470 mg
Artemether‑lumefantrine tablet 20/120 mg
Non‑quality assured ACT
Not listed, unknown manufacturer
Approval at national 
level
Colart®, Glaxosmithkline Group Of Com‑
panies, India
Artemether‑lumefantrine tablet 20/120 mg Non‑quality assured ACT Unknown
Combimal®, Ajanta Pharma Ltd, India/
Mauritius
SP tablet 500/25 mg Non‑artemisinin therapy Unknown
Darte‑Q®, Gosun Pharma Corp, China Dihydroartemisinin‑piperaquine tablet 
40/320 mg
Non‑quality assured ACT Unknown
Duo‑Cotecxin®, Beijing Holley‑Cotec 
Pharmaceutical Ltd, China
Dihydroartemisinin‑piperaquine tablet 
40/320 mg
Non‑quality assured ACT Unknown
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samples analysed failed the TLC 0.5% (95% CI 0.08–
1.84%). The first failed sample was AL 20/120 mg (Coar-
tem®) (Figure 2), with batch number F2261, manufacture 
date 01.2012 and expiry date 01.2016. This sample was col-
lected in a pharmacy in Bitam, a town 30 km south of the 
border with Cameroon. The genuine product is manufac-
tured by Novartis and is a WHO pre-qualified medicine 
(Table 2). This sample did not contain any APIs. Storage 
conditions in Gabon or during transport are not expected 
to have been of any influence, given AL’s excellent stabil-
ity profile in humid and hot conditions [43]. This batch 
number is also known to be falsified: in November 2013, 
a drug alert of the WHO was issued describing falsified 
batches of Coartem® circulating in Cameroon [44]. The 
sample bears the falsified green leaf logo of the Affordable 
Medicines Facility—Malaria (AMFm) programme. There 
were actually made of calcium phosphates, fatty acids and 
yellow pigment, according to a copy of a Novartis analy-
sis of the tablets reviewed by The Wall Street Journal [45, 
46]. Another important clue for falsification is the inter-
val between manufacturing and expiry date, which was 
4 years in this sample, but should be 23 months.
The other sample that failed TLC testing was SP 
500/25  mg, Maloxine® (Batch No. EM-304; Mfg. date: 
04/2011; Exp. Date 08/2014; Code: MH/DRUGS/670 
(Figure  3). No packaging analysis of the second failed 
A classified product—listed on WHO prequalification list, B classified product—Stringent National Drug Regulatory Authority Registration letter/Marketing 
Authorization. ACT Watch Antimalarial Database: (http://www.actwatch.info/databases/antimalarial_survey_data/az) WHO prequalification. (http://apps.who.int/
prequal/query/ProductRegistry.aspx).
Table 2 continued
Brand name/manufacturer Generic name and dose ACT Watch Antimalarial 
Database
Antimalarial category
Regulatory 
status in 
Gabon
Falquin®, Plethico pharmaceutical Ltd, 
India
Quinine tablet 300 mg. Not listed, manufacturer unknown Unknown
Fansidar®, F.Hoffmann La Roche Ltd, 
Switzerland
SP tablet 500/25 mg Non‑artemisinin therapy Unknown
Lariam®, F.Hoffmann La Roche Ltd, 
Switzerland
Mefloquine tablet 250 mg Non‑artemisinin therapy, country of 
manufacture not listed
Unknown
Laritem®, IPCA Laboratories Ltd, India Artemether‑lumefantrine 20/120 mg
Artemether‑lumefantrine 80/480 mg
Non‑quality assured ACT
Dosage not listed
A (MA062, 2009‑
Dec‑15)
WHO prequalifica‑
tion
Lufanter®, Bliss Gvs Pharma Ltd, India Artemether‑lumefantrine 20/120 mg and 
80/480 mg
Non‑quality assured ACT Approval at national 
level
Lumart®, Cipla Ltd, India Artemether‑lumefantrine tablet 20/120 mg
Artemether‑lumefantrine tablet 40/240 mg
QAACT (Quality‑assured ACT)
Dosage not listed
A (MA064, 2009‑
May‑22) WHO 
prequalification
Malacur®, Elder pharmaceuticals LTD, 
India
Dihydroartemisinin‑piperaquine tablet 
40/320 mg
Non‑quality assured ACT
Brand known, manufacturer not listed
Approval at national 
level
Malanil®, Glaxosmithkline Group  
Of Companies, Canada
Atovaquone‑proguanil tablet 250/100 mg Non‑artemisinin therapy Unknown
Maloxine®, Gracure Pharmaceuticals  
Ltd, India
SP tablet 500/25 mg Non‑artemisinin therapy
Brand known, manufacturer not listed
Unknown
Mephaquin®, Mepha Ltd, Switzerland Mefloquine tablet 250 mg Non‑artemisinin therapy Unknown
P‑Alaxin®, Bliss Gvs Pharma Ltd, India Dihydroartemisinin‑piperaquine tablet 
40/320 mg
Non‑quality assured ACT Approval at national 
level
Paludrine®, Astra Zeneca UK Limited, 
United Kingdom
Proguanil tablet 100 mg Prophylaxis B
Pharmasucam®, Madras Pharmaceuticals, 
India
Artesunate‑amodiaquine 100/270 mg Not listed, brand name and manufac‑
turer unknown
Unknown
Quinimax®, Sanofi Aventis, Spain Quinine 500 mg and 125 mg Non‑artemisinin therapy Unknown
R‑Lume®, Impact Healthcare  
Pvt Ltd, India
Artemether‑lumefantrine tablet 80/480 mg Not listed, brand name and manufac‑
turer unknown
Unknown
Savarine®, AstraZeneca Ltd, France Proguanil‑chloroquine tablet 200/100 mg Not listed Unknown
Sharlum®, Sharon Big‑medicine  
Ltd, India
Artemether‑lumefantrine tablet 80/480 mg and 
40/240 mg
Not listed, brand name and manufac‑
turer unknown
Unknown
Surquina®, Laboratoire Innotech Interna‑
tional, France
Quinine tablet 250 mg Non‑artemisinin therapy Unknown
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sample was conducted, as results of previous attempts to 
collect genuine samples and batch information from the 
stated manufacturer for comparative assessment were 
unsuccessful.
There was no statistic significant difference (Fisher’s 
exact test, P  =  0.311) in the number of poor-quality 
drugs collected by the Gabonese mystery shopper versus 
two European researchers (BJV and DK).
High‑performance liquid chromatography (HPLC) 
and artemisinin derivative screening test (ADST)
Both the ARST test (no colour produced) and HPLC 
(no peak on the spectra) analysis indicated the absence 
of API in the sample of Coartem® batch no. F2261. In the 
suspect Maloxine® sample batch no. EM-304 the stated 
APIs were detected, but the amount was approximately 
half the dose.
Disintegration test
In total, 266 samples (62%) were tested for disintegration. 
Not all (n = 432) samples were tested because one disin-
tegration test requires six tablets per test. Samples were 
tested per batch. One sample (0.4%) failed the disintegra-
tion test (Coartem® sample that also failed the TLC and 
HPLC). The disintegration time of the Maloxine® sam-
ple that failed the TLC test could not be tested, because 
the SP sample contains only three tablets in total. For 
detailed results of disintegration test per batch number 
see Additional file 5.
Manufacturers and registration status
Forty-three different brands were collected. Most pack-
agings/accompanying leaflets of the drugs sampled stated 
the countries of manufacture to be India (n = 148, 34%) 
and China (n = 71, 16%) (Figure 4). Only five anti-malar-
ial drug brands (87/432, 20% of samples) had obtained 
WHO prequalification: Coartem®, (n  =  40, Novartis 
Pharma Ag); Lumart®, (n = 3, Cipla Ltd); Laritem®, (n = 3, 
IPCA Laboratories Ltd); Coarsucam®, (n  =  22, Sanofi 
Aventis) and Artefan®, (n  =  19, Ajanta Pharma Ltd). 
Figure 2 The suspect Coartem® sample, having failed semi‑quantitative thin‑layer chromatography.
Figure 3 The suspect Maloxine® sample, having failed semi‑quantita‑
tive thin‑layer chromatography. The manufacturer is wrong to allege 
that it is the “only single dose treatment of malaria”.
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For many brands, the registration status in Gabon is 
unknown (Table 2).
Questionnaire
In total, 209 adults randomly selected from street and 
market crowds participated in the survey [47]. As a rule of 
thumb, every fifth passer-by was approached to participate 
in the survey. Forty-one participants were interviewed at 
the market in Lambaréné, 98 at the market Mont Bouët 
in Libreville and 70 at PK8 (transport hub) in Libreville. 
For 203 people, data were complete; 92% (187/203) of the 
interviewed people purchased their anti-malarial drugs in 
a pharmacy, 3.4% in a hospital, 3.4% in a dispensary and 1% 
(2/203) on the market. Some 51% of the people reported to 
have a CNAMG (La Caisse Nationale d’Assurance Mala-
die et de Garantie Sociale du Gabon) health insurance, 
which means they receive anti-malarial drugs for free in 
CNAMG affiliated and licensed pharmacies. For detailed 
results of the questionnaire, see Additional file 6.
Costs of this study
The total cost of this study [29] were: €7,578 including 
the purchase of samples, shipment of samples, trans-
portation costs of the researchers and chemical analysis 
(GPHF Minilab™ = 4,491, €40, HPLC = in kind contribu-
tion), but excluding personnel costs and article-process-
ing charges (Additional file 2).
Discussion
This study represents the first systematic and nationwide 
field survey of anti-malarial drug quality in Gabon. The 
results are reassuring, as it has been demonstrated that poor-
quality anti-malarial drugs were uncommon—only 0.5% 
of all samples failed the chemical analysis (TLC) and only 
one sample (AL, Coartem®) could be classified as falsified. 
The other sample (SP, Maloxine®) was considered as sub-
standard as it contained half of the stated dose. The Coar-
tem® AL 20/120 mg sample that failed chemical testing was 
collected in a small pharmacy in Bitam, a town close to the 
border with Cameroon. This sample is a known fake [44]. In 
Cameroon, it was found that a large proportion of samples 
contained either no active ingredient, insufficiently active 
ingredient, the wrong ingredient, or unknown/unidentifiable 
ingredient(s) [5]. The authors do not know how this falsi-
fied sample ended up for sale in the pharmacy; probably this 
pharmacy purchased the drugs not via the regular route (the 
central pharmacy in Libreville), but via drug traders.
Reassuring was that no oral artesunate monotherapy 
was found. The results of this study are in strong contrast 
with findings from neighbouring countries [12], where 
high prevalence of poor-quality anti-malarial drugs 
have been reported. Using a randomized sampling col-
lection method, fewer poor-quality anti-malarial drugs 
were identified, compared to previous reports using 
convenience-sampling methods. A systematic review in 
2014 showed that only 5% (six) of 130 published reports 
included evidence for randomization of sample location 
selection [12].
The findings of the present study emphasize the need 
for randomized and reliable sampling methods in order 
to obtain reliable information on anti-malarial drug qual-
ity in a country. It also underpins the notion that there 
are important caveats to accurately estimate the preva-
lence and distribution of poor-quality anti-malarials, and 
that the problem may not be as universally massive as is 
suggested in the literature [12].
The low proportion of failures could also be explained 
by the fact that in Gabon, drugs importation and 
Figure 4 Stated origin of the collected samples. Green Asia, Red Europe, Orange North America.
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provision to pharmacies may be subject to better-
enforced import regulation compared to other African 
countries. Theoretically (only, because income is une-
venly distributed in Gabon), the average Gabonese resi-
dent may be more affluent (Gabon is an upper-middle 
income country), and thus have easier access and confi-
dence to pharmacies for drug purchase.
A substantial amount of samples (brands) were not 
WHO-prequalified but registered at national level and 
refunded by the CNAMGS in Gabon [48, 49]. Registra-
tion of anti-malarials with no internationally regulatory 
clearance at national level may reflect a weakness in the 
regulatory system of Gabon.
Strengths and limitations of study
The sample size in this study is appropriate to make 
generalizations about the quality of anti-malarial drugs 
in Gabon. Although the samples analysed in the current 
study were only collected from pharmacies (and not 
from markets, street vendors, etc.), the results arguably 
represent the situation in Gabon. In the experience of 
the authors and researchers at CERMEL, and as con-
firmed by the questionnaire results, it is known that 
most residents purchase their medicines in pharmacies 
or hospitals. Moreover, 92% of the interviewed peo-
ple in this study reported to buy their drugs in a phar-
macy, although having given ‘socially desirable answers’ 
cannot be excluded from this questionnaire. Another 
limitation of the street questionnaire is that it was con-
ducted in only two cities: Lambaréné and the capital, 
Libreville. Therefore, these results may differ for other 
areas of Gabon.
Other strengths of this study are the randomized 
design and the use of a mystery shopper for the collection 
of samples [50]. The 11 surveyed cities/towns cover the 
majority of the relatively small population of Gabon. As 
can be seen on the map, towns are not evenly distributed 
across the country; most people live in the west, as the 
east of Gabon comprises large inaccessible tropical for-
est areas. All border areas were also covered in this sur-
vey: Equatorial Guinea (Libreville and Oyem), Cameroon 
(Bitam and Oyem), Congo (Franceville, Mouila).
The GPHF Minilab® (semi-quantitative layer chro-
matography) was used to evaluate the quality of anti-
malarial drugs. This method does not require specialist 
training, is simple to use, rapid, robust, reproducible, 
relatively inexpensive (HPLC of all the samples costs 
approximately €14,000), and has successfully detected 
poor-quality drugs before [37, 38, 51–55]. However, it 
is a screening tool able to give qualitative results as the 
sensitivity of the method is limited [56]. This means that 
false negatives might be present. A study conducted by 
the WHO in six African countries [22] compared the 
outcomes of quality control laboratory testing and the 
GPHF-Minilab® screening. It was shown that Minilab 
screening detected only approximately one in three non-
compliant samples. Furthermore, Minilab screening gave 
some false positive results: 6 of 99 ACT samples (6%) and 
1 of 92 SP samples (1%) failed in GPHF-Minilab® screen-
ing, but complied with all specifications in quality control 
laboratory testing. Thus, it can only reliably detect grossly 
sub-standard samples and therefore should not be used 
as an independent testing resource or provide quantita-
tive data except in conjunction with a laboratory capable 
of more sensitive techniques, e.g., HPLC [52].
In this study, the two failed samples were analysed at 
the reference laboratory based at the London School of 
Hygiene and Tropical Medicine (LSHTM). Unfortu-
nately, funds were insufficient to analyse all the ‘passed’ 
samples with HPLC to get a quantitative assessment of 
samples. However, even if the results underestimate the 
prevalence with a hypothetical factor 3, the prevalence 
of poor-quality drugs would be around 1.5%, which is 
still low (although significant in terms of morbidity and 
mortality). Thus, the GPHF Minilab® can be useful as a 
screening tool of anti-malarial drugs through the use of 
semi-quantitative tests while results of a more thorough 
and confirmatory laboratory tests are awaited (e.g., mass 
spectrometry (FI-GRSA-MS) and HPLC) [57].
Conclusion
Poor-quality anti-malarials are, according to described 
findings, uncommon in Gabon. Nevertheless, the Gabo-
nese health authorities should lead an effort to improve 
regulatory requirements and consolidate regulatory func-
tions, as recommend by WHO. It could also consider 
publishing and disseminating granted licences for drug 
manufacturers to improve the regulation of imported 
drugs.
Additional files
Additional file 1: The medicine regulatory system in Gabon. This para‑
graph describes in brief the medicine regulatory system in Gabon.
Additional file 2: Study costs. To increase transparency and reproduc‑
ibility, the costs of this field survey are published. These include for exam‑
ple the laboratory costs, collection of the samples and travel expenses.
Additional file 3: CERMEL Scientific Review Committee’s study protocol 
assessment. The assessment of the Scientific Review Committee of the 
study protocol.
Additional file 4: Sample collection. The case record form or sample 
collection form depicts all the information collected during the sampling 
process.
Additional file 5: Results of the disintegration test. This documents 
shows the detailed results of the disintegration tests.
Additional file 6: AMQUAL questionnaire results. This documents sum‑
marizes the results of the street survey conducted.
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